advertisement
advertorial
Updated 12 September 2016

Asthma control in children now more affordable

Pharma Dynamics, South Africa’s leading supplier of cardiovascular medicine is pleased to announce the launch of SINTAIR tablets, effective therapy for asthma in children aged 2 years and older.

0

SINTAIR  (montelukast sodium equivalent to montelukast), is now available in cherry flavoured 4 mg and 5 mg chewable tablets, as well as 10 mg tablets for patients 15 years and older. Once daily SINTAIR has been registered for the prophylaxis and chronic treatment of atopic asthma, and offers a valuable treatment option to younger patients who may have difficulty using inhalers, causing dose delivery and associated outcomes to be variable. 

SINTAIR tablets are effective therapy for asthma in children aged 2 years and older. Similarly, in adolescents and adults, SINTAIR improves multiple parameters of asthma control and is considered to be a useful additional in the step-up approach, or combination therapy, for moderate and severe persistent asthma not controlled with inhaled corticosteroids.

SINTAIR is now available to your patients at up to 47 % less than the originator montelukast. (1)

SINTAIR is available in 3 dosage strengths:

  • SINTAIR 4mg, Montelukast sodium equivalent to 4mg montelukast, 30 chewable tablets, R150.00
  • SINTAIR 5mg, Montelukast sodium equivalent to 5mg montelukast, 30 chewable tablets, R150.00
  • SINTAIR 10mg, Montelukast sodium equivalent to 10mg montelukast, 30 tablets, R150.00

The package insert as approved by the Medicines Control Council is available upon request from Karin Bissolati at (021) 707 7000 or email k.bissolati@pharmadynamics.co.za

Marc Wilensky
Group Product Manager
(021) 707 7000

S3 Sintair 4 mg. Each tablet contains montelukast sodium equivalent to 4 mg montelukast. Reg. No. 44/10.2.2/0829
S3 Sintair 5 mg. Each tablet contains montelukast sodium equivalent to 5 mg montelukast. Reg. No. 44/10.2.2/0830
S3 Sintair 10 mg. Each tablet contains montelukast sodium equivalent to 10 mg montelukast. Reg. No. 44/10.2.2/0831

For full prescribing information, refer to the package insert approved by the Medicines Regulatory Authority.

Reference:
(1) The Department of Health website. http://www.doh.gov.za – Accessed 10/05/2013.

 
advertisement